Cart
sales@molnova.com
ELOVL1-IN-1
CAS No. 2227482-41-7
ELOVL1-IN-1( 1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide )
Catalog No. M28774 CAS No. 2227482-41-7
ELOVL1-IN-1 is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 353 | In Stock |
|
| 5MG | 321 | In Stock |
|
| 10MG | 472 | In Stock |
|
| 25MG | 846 | In Stock |
|
| 50MG | 1181 | In Stock |
|
| 100MG | 1535 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameELOVL1-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionELOVL1-IN-1 is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).
-
DescriptionELOVL1-IN-1 is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).(In Vitro):Administration of 1 nM-10 μM ELOVL1-IN-1 for 48 h reduces the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia.(In Vivo):Oral dministration of ELOVL1-IN-1 reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout mice (0.5-64 mg/kg; 28 days), wild‐type (WT) rats (30-300 mg/kg; 7 days), and cynomolgous monkeys (30 mg/kg; 7 days).
-
In VitroELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia.
-
In VivoELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days).
-
Synonyms1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide
-
PathwayOthers
-
TargetOther Targets
-
RecptorAhR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2227482-41-7
-
Formula Weight340.33
-
Molecular FormulaC18H14F2N4O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (293.83 mM)
-
SMILESO=C(C1(CC1)c(cccc1)c1F)Nc(cc1)nn1-c1cc(F)ncc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Current Patent Assignee: MAGENTA THERAPEUTICS INC - WO2020/51207, 2020, A2
molnova catalog
related products
-
HTBA
HTBA is a low-cost enzymatic paper-based analytical device (enz-PAD) for determining urine creatinine.
-
[pY185]MAP (177 - 18...
[pY185]MAP (177 - 189) kinase
-
PKC ζ pseudosubstrat...
Inhibitor of protein kinase C (PKC) ζ; attached to cell permeabilisation Antennapedia domain vector peptide. Consists of amino acids 113 - 129 of PKC ζ pseudosubstrate domain linked by a disulphide bridge to the Antennapedia domain vector peptide. The Antennapedia peptide is actively taken up by intact cells, at 4 or 37°C, ensuring rapid and effective uptake of the inhibitor peptide. Once inside the cell, the disulphide bonds are subjected to reduction in the cytoplasm leading to release of the inhibitor peptide. Induces mast cell degranulation by a PKC ζ-independent pathway.
